Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD2 | P25440 | 15/20 | 0.54 |
| ▸ | BRD4 | O60885 | 13/20 | 0.54 |
| ▸ | BRD3 | Q15059 | 9/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TAF1 | P21675 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11907819 | 1.00 | BRD2 (0.54) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL11909973 | 1.00 | BRD2 (0.54) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL11909997 | 0.93 | BRD4 (0.48) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL26129674 | 0.85 | BRD4 (0.66) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL221738 | 0.84 | BRD4 (0.76) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL1908120 | 0.84 | BRD4 (0.76) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL1908119 | 0.84 | BRD4 (0.76) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL11978797 | 0.84 | BRD4 (0.59) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL5836500 | 0.84 | BRD4 (0.65) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL5836498 | 0.84 | BRD4 (0.65) | BRD2BRD4BRD3HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023196512-A1 | PROPARGYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE BRD4 | Plexium, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST JUDE CHILDRENS RES HOSPITAL (US) | 2021-06-24 | — | — | US | disclosed |
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200079739-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2020-03-12 | — | — | US | disclosed |
| US-20190142949-A1 | COVALENT CONJUGATES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-3191476-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-10-24 | — | — | EP | disclosed |
| US-10059699-B2 | Tetrahydroquinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-28 | — | — | US | disclosed |
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2018111805-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20140066459-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2699551-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2699550-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140039006-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2496557-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012143413-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143415-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| EP-2496557-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | BRD4, BRDT, BRD3 | BRD2 4/4885BRD4 1/4885BRD3 3/4885 |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | BRD2 690/4885BRD4 240/4885BRD3 1040/4885 |
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | BRD2 4/4885BRD4 2/4885BRD3 3/4885 |
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | BRDT, BRD4, BRD3 | BRD2 4/4885BRD4 2/4885BRD3 3/4885 |
| US-20190142949-A1 | COVALENT CONJUGATES | BET1, RABGGTB, BRD4 | BRD2 11/4885BRD4 3/4885BRD3 7/4885 |
| US-20140039006-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | BRD4, BRDT, BRD3 | BRD2 4/4885BRD4 1/4885BRD3 3/4885 |
| US-20200079739-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | BRDT, BRD4, BRD3 | BRD2 4/4885BRD4 2/4885BRD3 3/4885 |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | BRD2 4/4885BRD4 2/4885BRD3 3/4885 |
| US-20140066459-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | BRD4, BRDT, BRD3 | BRD2 4/4885BRD4 1/4885BRD3 3/4885 |
| US-10059699-B2 | Tetrahydroquinoline derivatives as bromodomain inhibitors | BRD4, BRDT, BRD3 | BRD2 4/4885BRD4 1/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.